Korea’s biopharmaceutical industry is facing corporate restructuring. Both global and Korean pharmaceutical companies are undergoing aggressive employee reductions.

AstraZeneca Korea is implementing a voluntary resignation as a follow-up measure related to the withdrawal of Forxiga, a diabetes treatment, from the Korean market. The company is reducing its employees and offering an Early Retirement Plan (ERP) compensation package.

Pfizer Korea is also planning to implement a voluntary resignation program. Since Pfizer’s headquarters in the United States is reducing employees as part of its cost realignment program, the extent of the staff reduction for the Korean subsidiary of P